Neuroglycopenic symptoms result from inadequate glucose supply to the central nervous system and can range from mild manifestations, such as blurred vision, lightheadedness, flushing, lethargy, and weakness, to more severe consequences, including seizures, unconsciousness, disorientation, and speech difficulties [44]
What Drugs Are Available
However, clinically significant pancreatic enzyme elevations were rare
To better understand these connections and evaluate GLP-1RAs potential as a therapeutic approach for treating skeletal frailty in diabetes patients, especially the elderly more extensive long-term research is required (65)
The success of these therapies has paved the way for the development of next-generation treatments, including multi-agonist molecules like Tirzepatide (Mounjaro/Zepbound) or Retatrutide (LY3437943) that simultaneously target several metabolic receptors to achieve improved metabolic outcomes in obese or diabetic patients [3,6]
The development of generic alternatives of GLP-1 agonists by several pharma companies increases the accessibility for many people, helping them to reduce weight
